NeuroDerm is developing ND0612H for the treatment of severe stage Parkinson’s disease patients for whom oral drugs are no longer effective. ND0612H has been designed to be a safer, more effective and convenient alternative to current treatment modalities that involve surgery, such as deep brain stimulation (DBS) and levodopa/carbidopa intestinal gel (LCIG, Duodopa in Europe and Duopa in the United States).
ND0612H belt pump
A simple, daily, convenient drug pump that delivers LD/CD to treat severe Parkinson’s disease patients.
ND0612H has been designed to provide continuous subcutaneous delivery of an adjustable, high dose, LD/CD formulation to significantly improve motor and non-motor complications in patients refractory to oral LD/CD.
ND0612H’s subcutaneous administration – utilizing a convenient belt-pump (resembling the administration of insulin to diabetic patients) – allows patients to receive continuous LD/CD therapy on a 24 hour basis, thus avoiding morning “off” time and ensuring a good night’s sleep.
NeuroDerm believes that ND0612H will be a first-line treatment alternative for advanced Parkinson’s patients, preceding and replacing the surgical treatment alternatives currently offered to severe stage patients.
NeuroDerm completed a Phase IIa dose-finding trial with ND0612H. In this study, the plasma levodopa concentrations achieved in individual Parkinson’s disease patients treated with ND0612H and ND0612L for eight hours, were examined. The resutls showed that ND0612H achieved an average maximum plasma levodopa concentration of approximately 1500ng/ml when administered alone and an average maximum plasma levodopa concentration of approximately 1800ng/ml when combined with two administrations of oral entacapone during eight hours of infusion. The high average plasma levodopa concentrations achieved with ND0612H in this trial indicate that ND0612H may offer a viable alternative to more invasive surgical procedures for advanced Parkinson’s Disease.